Bottom line
Is MEDX a good fund? The bottom line
MEDX is an actively managed health care sector ETF from Roundhill.
Its expense ratio is 0.85% — about $85 a year on every $10,000 invested, cheaper than 57% of health care sector funds we track.
It returned +28.4% over one year, +5.8% a year over five years, +5.7% a year over ten (as of Dec 31, 2025, per its prospectus).
With $19.1 million in net assets and 33 holdings, its largest position is Eli Lilly & Co (18.5%) and the top 10 make up 72.4% of the portfolio.
What stands out
- 5-year return beat 70% of category peers
What to watch
- Concentrated: top 10 holdings are 72.4% of assets
- Small fund ($19.1 million) — small funds are likelier to close
Updated Nov 19, 2026
What MEDX invests in
Horizon Kinetics Medical ETF ( Medical ETF or the Fund) seeks to provide long-term growth of capital.
The Fund is an actively managed exchange-traded fund (ETF) that pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets plus any borrowings for investment purposes in common stocks, convertible securities, warrants and other equity securities having the characteristics of common stocks (such as American Depositary Receipts (ADRs), Global Depositary Receipts (GDRs) and International Depositary Receipts (IDRs)) of U.S. and foreign companies engaged in medical research, pharmaceutical and medical technology industries and related technology industries, generally, with an emphasis toward companies engaged in cancer research and drug development, such as pharmaceutical development companies, surgical and medical instrument manufacturers and developers, pharmaceutical manufacturers, and biotech and medical research companies. These types of…
From the fund's prospectus (filed Apr 27, 2026).
MEDX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| MEDX | +28.4% | +5.8% | +5.7% |
| Health Care Sector median | +14.5% | +4.2% | +7.9% |
Source: Fund prospectus, as of Dec 31, 2025
What MEDX costs
On a $10,000 investment, MEDX's 0.85% expense ratio costs about $85 a year. The prospectus estimates $1,049 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
MEDX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Eli Lilly & Co LLY | 18.46% |
| 2 | US Bank Mmda - Usbgfs 7 | 9.19% |
| 3 | AbbVie Inc ABBV | 8.85% |
| 4 | Novartis AG NVS | 6.89% |
| 5 | Johnson & Johnson JNJ | 5.59% |
| 6 | Alkermes PLC ALKS | 5.53% |
| 7 | AstraZeneca PLC AZN | 4.98% |
| 8 | Ionis Pharmaceuticals Inc IONS | 4.53% |
| 9 | Bristol-Myers Squibb Co BMY | 4.42% |
| 10 | Merck & Co Inc MRK | 3.96% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 72.4% of the fund. See all top 25 holdings and asset mix →